Skip to main
ALKS
ALKS logo

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 46%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Alkermes PLC is experiencing a positive outlook due to the demonstrated efficacy of its product alixorexton, which has shown normalization across key wakefulness measures in patients with narcolepsy type 1 (NT1). The quantitative analyses have provided incremental confidence in the potential of alixorexton, particularly noting rapid normalization of the Epworth Sleepiness Scale (ESS) scores at week 2, with sustained responses during the open-label extension period. This efficacy not only underscores the product's therapeutic potential but also positions Alkermes favorably within the competitive landscape of unmet medical needs.

Bears say

Alkermes PLC's recent clinical data demonstrated mixed results for its product alixorexton, particularly related to the weekly cataplexy rate, which only achieved statistical significance at the 6mg dosage but showed variability due to outliers. The inconsistency in patient-reported outcomes raises concerns about the product's efficacy and marketability, potentially undermining investor confidence. Furthermore, the company's reliance on proprietary technologies and external partnerships for drug formulation may limit its control over product quality and therapeutic effectiveness, contributing to a negative outlook on its stock.

Alkermes (ALKS) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 46% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 13 analysts, Alkermes (ALKS) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.